CRISPR Therapeutics AG [NASDAQ:CRSP]: Analyst Rating and Earnings
Equities traders often pay a significant amount of attention to what top market analysts have to say about a potential stock investment. In regards to CRISPR Therapeutics AG [CRSP], the most recent average analyst recommendation we can read comes from the fiscal quarter ending in December. On average, stock market experts give CRSP an Outperform rating. The average 12-month price forecast for this stock is $63.06, with the high estimate being $78.00, the low estimate being $28.00 and the median estimate amounting to $65.00. This is compared to its latest closing price of $36.73.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for CRISPR Therapeutics AG [CRSP] is sitting at 2.36. This is compared to 1 month ago, when its average rating was 2.36.
Keep your eyes on this company’s next financial results, which are scheduled to be made public on Thu 14 Mar (In 62 Days).
Fundamental Analysis of CRISPR Therapeutics AG [CRSP]
Now let’s turn to look at profitability: with a current Operating Margin for CRISPR Therapeutics AG [CRSP] sitting at -157.69. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -30.74, and its Return on Invested Capital has reached -32.00%. Its Return on Equity is -32.50, and its Return on Assets is -22.18. These metrics suggest that this CRISPR Therapeutics AG does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is -21.58. The Enterprise Value to Sales for this firm is now 37.59. CRISPR Therapeutics AG [CRSP] has a Price to Book Ratio of 5.07.
Shifting the focus to workforce efficiency, CRISPR Therapeutics AG [CRSP] earns $322,811 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 14.18 and its Total Asset Turnover is 0.13. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 17.12 and its Current Ratio is 17.12. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: CRISPR Therapeutics AG [CRSP] has 51.21M shares outstanding, amounting to a total market cap of $1.77B. Its stock price has been found in the range of 22.22 to 73.90. At its current price, it has moved by -53.22% from its 52-week high, and it has moved 55.58% from its 52-week low.
This stock’s Beta value is currently , which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 55.65. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is CRISPR Therapeutics AG [CRSP] a Reliable Buy?
CRISPR Therapeutics AG [CRSP] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.